lawyer

Watch a video featuring the Microbiology and Virology PhD Graduate School Program.

Students: Leighland Feinman, Nicole Glennon, Grant Beyleveld, Ryan O'Hanlon

Postdoctoral fellows: Oliver Dibben, Ph.D. Yuhong Liang, Ph.D. Kris White, Ph.D. Matthew Urbanowski, Ph.D. Thibaut Vausselin, Ph.D.

Research Personnel: Pablo Abreu Jr. Payal Pradhan

The Shaw laboratory is interested in the interactions that occur between RNA viruses and their hosts at the molecular level and how this knowledge may be used for understanding viral pathogenesis and for developing new antiviral drugs. The research involves basic molecular biology and virology techniques combined with RNAi, proteomics and high-throughput screening of small molecular weight compounds.

Our major focus is on identifying new antivirals for influenza virus as well as host proteins that are required by the virus and therefore may serve as novel drug targets. Another interest of the Shaw lab is the host antiviral response and specifically the mechanisms that viruses use to block this response. One virus of particular interest to us is Nipah virus, with is a highly pathogenic, emerging paramyxovirus. Nipah virus encodes multiple proteins that inhibit the antiviral response and our goal is to determine their mechanisms of action and their individual contributions to virus pathogenesis.

Park MS, Shaw ML, Munoz-Jordan J, Cros JF, Nakaya T, Bouvier N, Palese P, Garcia-Sastre A, Basler CF. Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. Journal of virology 2003 Jan; 77(2).

Shaw ML, Garcia-Sastre A, Palese P, Basler CF. Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. Journal of virology 2004 Jun; 78(11).

Shaw ML, Cardenas WB, Zamarin D, Palese P, Basler CF. Nuclear localization of the Nipah virus W protein allows for inhibition of both virus- and toll-like receptor 3-triggered signaling pathways. Journal of virology 2005 May; 79(10).

Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, Carbonnelle C, Volchkov VE, Nichol ST, Basler CF. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. Journal of virology 2006 Jun; 80(11).

Palese P, Shaw ML. Orthomyxoviridae: The Viruses and Their Replication. In: Fields Virology 5th edition. Philadelphia, Lippincott Williams & Wilkins; 2007. pp1647-1689.

Shaw ML, Stone KL, Colangelo CM, Gulcicek EE, Palese P. Cellular proteins in influenza virus particles. PLoS pathogens Jun; 4(6).

Hoffmann HH, Palese P, Shaw ML. Modulation of Influenza Virus Replication by Alteration of Sodium Ion Transport and Protein Kinase C activity. Antiviral Research ; 80: 124-134.

Palese P, Shaw ML. Orthomyxoviruses: Molecular biology. In: Encyclopedia of Virology 3rd edition. Oxford, U.K, Elsevier, . pp483-489.

Kulkarni S, Volchkova V, Volchkov V, Shaw ML. Nipah Virus Edits its P Gene at High Frequency to Express the V and W Proteins. Journal of Virology ; 83(8): 3982-7.

Shaw ML. Henipaviruses employ a multifaceted approach to evade the antiviral interferon response [review]. Viruses Dec; 1(3).

Ciancanelli MJ, Volchkova VA, Shaw ML, Volchkov VE, Basler CF. Nipah virus sequesters inactive STAT1 in the nucleus via a P gene-encoded mechanism. Journal of virology Aug; 83(16): 7828-41.

Konig R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, Bhattacharyya S, Alamares JG, Tscherne DM, Ortigoza MB, Liang Y, Gao Q, Andrews SE, Bandyopadhyay S, De Jesus P, Tu BP, Pache L, Shih C, Orth A, Bonamy G, Miraglia L, Ideker T, Garcia-Sastre A, Young JA, Palese P, Shaw ML, Chanda SK. Human host factors required for influenza virus replication. Nature Feb; 463(7282).

Seto J, Qiao L, Guenzel CA, Xiao S, Shaw ML, Hayot F, Sealfon SC. Novel Nipah virus immune-antagonism strategy revealed by experimental and computational study. Journal of virology Nov; 84(21).

Stertz S, Shaw ML. Uncovering the global host cell requirements for influenza virus replication via RNAi screening [review]. Microbes and infection / Institut Pasteur May; 13(5).

Hoffmann HH, Kunz A, Simon VA, Palese P, Shaw ML. A broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proceedings of the National Academy of Sciences of the United States of America Apr; 108(14).

Shaw ML. The host interactome of influenza virus presents new potential targets for antiviral drugs [review]. Reviews in medical virology Nov; 21(6).

Shaw ML, Palese P. Orthomyxoviridae: The Viruses and Their Replication. In: Fields Virology 6th edition. Philadelphia, Lippincott Williams & Wilkins;.

Ortigoza MB, Dibben O, Maamary J, Martinez-Gil L, Leyva-Grado VH, Abreu P, Ayllon J, Palese P, Shaw ML. A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferon. PLoS pathogens ; 8(4).

Martinez-Gil L, Ayllon J, Ortigoza MB, Garcia-Sastre A, Shaw ML, Palese P. Identification of small molecules with type I interferon inducing properties by high-throughput screening. PloS one ; 7(11).

Martinez-Gil L, Goff PH, Hai R, Garcia-Sastre A, Shaw ML, Palese P. A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant. Journal of virology Feb; 87(3).

Alamares-Sapuay JG, Martinez-Gil L, Stertz S, Miller MS, Shaw ML, Palese P. Serum- and glucocorticoid-regulated kinase 1 is required for nuclear export of the ribonucleoprotein of influenza A virus. Journal of virology May; 87(10).

Beyleveld G, White KM, Ayllon J, Shaw ML. New-generation screening assays for the detection of anti-influenza compounds targeting viral and host functions [review]. Antiviral research Oct; 100(1).

Shaw ML, Klumpp K. Successes and challenges in the antiviral field [editorial]. Current opinion in virology Oct; 3(5).

Ortiz-Riano E, Ngo N, Devito S, Eggink D, Munger J, Shaw ML, de la Torre JC, Martinez-Sobrido L. Inhibition of arenavirus by A3, a pyrimidine biosynthesis inhibitor. Journal of virology Jan; 88(2).

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Shaw during and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.

• F. Hoffman-La Roche Ltd.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.

Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.

Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website .